@desertshores I have seen no HbA1c impact from my SLGT2 inhibitor (dapa).
2 Likes
adssx
#82
I agree that SGLT2i seem to have no impact on HbA1c in non-diabetic individuals. @desertshores: it’s possible that in your case metformin is the best solution. Acarbose might be interesting as well. And/or a GLP-1RA that does not cause too much weight loss such as dulaglutide.
2 Likes
Yes, I have found that SGLT2I does not lower a prediabetic HBA1C. Metformin does. However, the SGLT2I has done a great job getting me to drink more water and lose weight.
3 Likes
adssx
#84
To prevent pre-diabetes, I think the best will be proven to be GLP-1RAs. Recently, it was shown that “Tirzepatide reduced the risk of developing type 2 diabetes by 94% in adults with pre-diabetes and obesity or overweight”.
Would it work for non-overweight people? I don’t know; it would be good to look at the results of the above study stratified by BMI. I guess we’ll have more data soon.
3 Likes
No: here is a paper showing that metformin shortens lifespan in old worms, and wildly speculating that it will shorten lifespan in the elderly.
9 Likes
Before they reach clinical trials, drugs have to be found effective in animal models (usually rodents) and tested for basic safety in two other mammalian species. After all that, 90% of drug candidates in clinical trials fail.
2 Likes
I must’ve missed this.
I began dosing like this for just a month with no discernable effects either way.
I had labs done three months ago so when I get my labs done next month I’ll be able to see if it moved any numbers.
1 Like
DrT
#88
Thanks for the correction!
I should realise by now…never trust memory alone!
1 Like
It makes a case for a possible mechanism for how metformin does what we already know it does in people with diabetes; it says nothing compelling about its use by normoglycemic people one way or the other.
Attia definitely did not look only at lactate. He also looked at the clinical trials that show that it impairs adaptations to both aerobic and resistance training exercise; the fact that the 2014 study claiming to show that diabetics who use metformin live longer than nondiabetics who don’t doesn’t actually show that; and the fact that it flopped in the ITP and in other lifespan studies done in normally-living mice.
Thanks for posting the information on Metformin and HIV. This was previously unknown to most of us who are living with HIV. In 12 years of treatment for this chronic infection, all I ever hear is about the expensive antiretroviral medications from big pharma. Larry.
1 Like
Beth
#91
I haven’t read everything in this thread and imagine this has already been posted, but I just read this and passing it along if helpful… probably a repeat!
1 Like
Really a great article. Thanks for posting that. I’ve not been a fan of metformin, apart form use in diabetics. I think there are better choices to improve insulin sensitivity in the brain and periphery.
It’s cheap, but my take is acarbose, GLP-1’s and SGLT2’s are the bomb … and metformin underperforms and with side effects of sarcopenia. For many individuals with a set point for insulin release from their pancreas being too high, metformin is amazing.
Otherwise, I think we have better options for most patients, despite the guidelines wanting this first.
5 Likes
Jonas
#95
Does metformin benefit the population with metabolic syndrome? YES
Does metformin has specific proven result for specific cancer? No
Does metformin have some benefit of slowing early stage tumor growth? Maybe
Do you experience benefit or harm while taking metformin? Please share.
Is Silicon Valley still high on metformin? No, they moved onto sglt2 inhibitors, other than Juan Carlos who strangely mentioned metformin as one of the agents recently.
And why on earth is Barzilai still at it? Why can’t he raise the money after all these years?
4 Likes
Beth
#97
Thank you for posting this. I have a friend losing his vision from this. I just forwarded this to his wife. Thx again
3 Likes
This might be worth sharing as well. Red light therapy for macular degeneration.
“ Glen Jeffrey is a Professor of Neuroscience in the Faculty of Brain Sciences and Institute of Ophthalmology at the University College London. His research focuses on areas including retinal structure, development and visual areas of the brain as well as comparative evolution of the brain. In the last decade, his work has been centred around public health, looking into cost-effective and safe ways to prevent and even reverse the increasingly common condition macular degeneration. His research has delved into the mechanisms that underpin the aging process and applied these findings to the most energy demanding cells in the body; the retinal cells.
In the last few years, Glen’s lab has been at the forefront of using light to restore the pathological condition of macular degeneration. By using wavelengths of red and near-infrared light at the correct time of day, Glen and his colleagues have shown that these wavelengths of light can help the organelles called mitochondria produce energy more efficiently, offsetting some of the damage caused by aging. This extremely low-cost modality with an unparalleled safety profile may indeed become something that is used widely in the future to prevent and restore metrics of vision in our aging population.”
Follow Glen’s Work Here:
Glen will be a guest on my show soon
6 Likes
Beth
#99
I’ll pass on this now AND that episode when it comes out!! Thank you so very much!!
2 Likes
It appears that Metformin may help with MS as it helps to rebuild your myelin sheaths in your brain.
3 Likes
